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DC-HIL-Expressing Myelomonocytic Cells Are Critical
Promoters of Melanoma Growth
Jin-Sung Chung1, Kyoichi Tamura1, Ponciano D. Cruz Jr1 and Kiyoshi Ariizumi1
A major barrier to successful cancer immunotherapy is the tumor’s ability to induce T-cell tolerance by exploiting
host regulatory mechanisms. Having discovered the DC-HIL receptor, which inhibits T-cell responses by binding
to syndecan-4 on effector T cells, we posited the DC-HIL/syndecan-4 pathway to have an important role in cancer
promotion. Among DC-HILþ myelomonocytic cells, during growth of implanted mouse melanoma, CD11bþ
Gr1þ cells were the most expanded population and the most potent at suppressing T-cell activation. Deletion of
the DC-HIL gene or infusion of anti-DC-HIL mAb abrogated these cells’ suppressor function and expansion, and
markedly diminished melanoma growth and metastasis. IL-1b and IFN-g were elevated in mice bearing melanoma,
and concurrent exposure to both cytokines optimally induced DC-HIL expression by tumor-infiltrating CD11bþ
Gr1þ cells. Ligation of DC-HIL transduced phosphorylation of its intracellular immunoreceptor tyrosine-based
activation motif, which in turn induced intracellular expression of IFN-g and inducible nitric oxide synthase
(iNOS), known to mediate T-cell suppression by CD11bþGr1þ cells. Thus, DC-HIL is the critical mediator of these
cells’ suppressor function in melanoma-bearing mice and a potential target for improving melanoma
immunotherapy.
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INTRODUCTION
Despite recent advances in the treatment of metastatic
melanoma, it remains the most lethal form of skin cancer, in
large part because of its ability to overcome host antitumor
immunity (Fang et al., 2008). Among immune mechanisms
exploited by melanoma are regulatory T cells, type-2 macro-
phages, immature dendritic cells (DCs), and CD11bþGr1þ
cells (which overlap with myeloid-derived suppressor cells
(MDSCs)) (Serafini et al., 2006). These latter cells are the most
potent suppressors of T-cell function.
CD11bþGr1þ cells consist of myeloid progenitors
(Gabrilovich and Nagaraj, 2009), which in healthy indivi-
duals are confined to the bone marrow (BM), where they
differentiate into DCs, granulocytes, or macrophages, none of
which are immunosuppressive. By contrast, in cancer patients,
differentiation is blocked by tumor-derived soluble factors,
causing these cells’ exponential proliferation and expansion
into blood and other organs, where they become immuno-
suppressive (Diaz-Montero et al., 2009).
CD11bþGr1þ cells were shown to suppress T-cell function
by producing inhibitory soluble factors such as urea/L-ornithine
(produced by arginase I) (Rodriguez and Ochoa, 2008), nitric
oxide (NO) (Bingisser et al., 1998), and reactive oxygen species
(Kusmartsev and Gabrilovich, 2003). Co-inhibitory pathways
such as CD80/86 (ligands for CTLA-4) and PD-L1 (for PD-1)
were shown to mediate suppressor function (Yang et al., 2006;
Liu et al., 2008, 2009), but inconsistently and sometimes in a
contradictory manner. Moreover, the molecular underpinning
for these cells’ suppressor function is not fully understood.
We discovered the DC-HIL receptor on antigen-presenting
cells (APCs), which binds syndecan-4 (SD-4) on effector/
memory (but not naive) T cells and downregulates T-cell
receptor (TCR) activation signals (Chung et al., 2007a, b). We
showed the DC-HIL/SD-4 pathway to inhibit inflammatory
responses in mouse models of contact hypersensitivity and
graft-versus-host disease (Chung et al., 2007a; Akiyoshi et al.,
2010). Furthermore, DC-HIL is expressed by melanoma cells,
and it suppresses T-cell activation via SD-4 on cytotoxic
T cells (Tomihari et al., 2010), but had little to no impact on
these cells’ tumor-killing activity.
Our present study heralds a melanoma-promoting role for
DC-HIL expressed by myelomonocytic cells bearing the
CD11bþGr1þ phenotype. Blocking DC-HIL function via
gene deletion or specific antibody (Ab) abrogated these cells’
suppression of T-cell function and promotion of melanoma
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growth. Ligated DC-HIL activated its intracellular immuno-
receptor tyrosine-based activation motif (ITAM) and induced
the expression of IFN-g and inducible nitric oxide synthase
(iNOS) (producing NO). Our findings indicate that DC-HIL is
responsible for secretion of T-cell–inhibitory factors by
CD11bþGr1þ cells, which render them immunosuppressive.
RESULTS
DC-HIL gene deletion inhibited the growth of melanoma
We created mice knocked out (KO) for the DC-HIL gene with
no gross abnormality nor developmental defects in lymphoid
organs, except for the absence of DC-HIL protein and whose
DCs are twofold greater activators of T cells than wild-
type (WT) counterparts (Supplementary Figure S1 and S2
online), thereby confirming DC-HIL’s inhibitory effect on
T-cell activation.
B16 melanoma subcutaneously inoculated into WT versus
DC-HIL / mice grew aggressively in the former, but its
growth was markedly inhibited in the latter (Figure 1a).
Having reported DC-HIL expression by B16 cells to promote
tumor growth by suppressing T-cell activation (Tomihari et al.,
2010), we probed this influence in DC-HIL / mice, using
B16 cells knocked down for DC-HIL (KD-B16). KD-B16
melanoma growth was slower than parental B16 melanoma,
and its growth was markedly inhibited in KO mice (Figure 1b).
We then examined lung metastasis (Figure 1c and d) following
i.v. (intravenous) injection of B16 cells: KO mice had
markedly lighter lungs, less metastatic foci, less melanin
content per lung, and less melanin per metastatic focus. Thus,
melanoma growth was supported by tumor-associated DC-HIL
and by host-derived DC-HIL.
DC-HIL is expressed by CD11bþGr1þ cells in mice bearing
melanoma
We next addressed which DC-HIL-expressing host cells
promote melanoma growth. As DC-HIL is expressed by
myelomonocytic cells (Chung et al., 2009), we identified the
most expanded DC-HILþ myeloid population from spleen of
mice with melanoma (Figure 2a), which turned out to be
CD11bþGr1þ cells, representing about 10% of splenocytes
(vs. CD11cþ DC or F4/80þ macrophages, which were about
5% each). Forty percent of splenic CD11bþGr1þ cells
expressed DC-HIL, whereas 20% and 66–73% of these cells
were, respectively, PD-L1þ and CD80/CD86þ (Figure 2b).
For CD11bþGr1þ cells from BM, blood, and the B16 tumor
site, DC-HIL expression ranged from 27 to 61% (Supplemen-
tary Figure S3a–c online). By contrast, CD11bþGr1þ cells
from tumor-free mice did not express DC-HIL (Figure 2c).
Thus, melanoma induced DC-HIL expression of some
CD11bþGr1þ cells in many organs.
Given DC-HIL’s T-cell–inhibitory function, we compared
the three subsets of DC-HIL-expressing myelomonocytic cells
for suppressor function (Figure 2d). Each was similarly assayed
for suppressor activity to carboxyfluorescein succinimidyl
ester-labeled T cells activated by anti-CD3/CD28 Ab. F4/80þ
macrophages or CD11cþ DCs did not inhibit T-cell prolifera-
tion even at the highest cell ratio (1:1), whereas CD11bþ
Gr1þ cells showed inhibition dose dependently. We next
examined their T cell–stimulatory capacity by mixing CD8þ
T cells from pmel-1 transgenic mice (in which all CD8þ
T cells express the same TCR specific for gp100 Ag) (Overwijk
et al., 2003) with each of the three DC-HILþ subsets pulsed
with gp100 peptide. CD11cþ DC or F4/80þ macrophages
induced strong T-cell proliferation at cell ratios of 1:0.25 or
higher (Figure 2e), whereas CD11bþGr1þ cells exhibited
similar stimulatory capacity at 1:0.25, while inhibiting T-cell
proliferation completely. Thus, CD11bþGr1þ cells in mice
with melanoma were the predominant DC-HIL-expressing
population and the most potent suppressors of T-cell
proliferation.
DC-HIL mediated the T cell –suppressive function of
CD11bþGr1þ cells
CD11bþGr1þ cells from melanoma-bearing mice were
cocultured with pmel-1 splenocytes and gp100 peptide at a
1:1 cell ratio; anti-DC-HIL mAb or control IgG was added to
block DC-HIL on CD11bþGr1þ cells (Figure 3a). The mAb
(but not control) restored pmel-1 T-cell activation dose
dependently and completely, but it had no effect on T-cell
activation without CD11bþGr1þ cells. Anti-CD80, anti-
CD86, or anti-PD-L1 Ab had no significant effect on CD11bþ
Gr1þ cells’ suppressor activity (Figure 3b). Thus, among the
co-inhibitors tested, DC-HIL was responsible solely for the
suppressor activity of CD11bþGr1þ cells.
We next compared the T-cell–suppressor capacity of
DC-HILþ versus DC-HILnegCD11bþGr1þ cells. Undepleted
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Figure 1. Growth and metastasis of B16 melanoma are suppressed in DC-
HIL / mice. (a) Tumor volume of B16 cells implanted into wild-type (WT) or
DC-HIL knocked-out (KO) mice (n¼ 5). (b) Tumor volume after implanting
DC-HIL-KD-B16 cells (n¼ 5). Lung metastasis (c) at 19 days after B16 cells
were injected i.v. into WT or KO mice (n¼ 10); lung weight, number of
metastatic foci, melanin content/lung, and melanin content/focus plotted (d).
Representative data from three separate experiments, *Po0.01 versus WT.
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CD11bþGr1þ cells inhibited gp100-triggered T-cell activa-
tion, whereas the DC-HIL-depleted CD11bþGr1þ fraction
showed no inhibition at all doses examined (Figure 3c).
In vivo suppressor ability of DC-HILþ cells was assessed by
injecting mice with pmel-1 CD8þ T cells, followed by
infusion of undepleted or DC-HIL-depleted CD11bþGr1þ
cells and by gp100 vaccination. Ten days later, mice infused
with CD8þ T cells but without CD11bþGr1þ cells generated
many activated (IFN-gþ ) T cells in lymph node (Figure 3d),
whereas co-infusion of undepleted CD11bþGr1þ cells led to
fewer activated T cells, and co-infusion of DC-HIL-depleted
CD11bþGr1þ cells prevented suppression. An experiment
using DC-HIL /CD11bþGr1þ cells showed similar results
(Supplementary Figure S4 online). Thus, DC-HILþ CD11bþ
Gr1þ cells were responsible for suppressor activity.
We next co-injected undepleted or DC-HIL-depleted
CD11bþGr1þ cells with B16 cells subcutaneously (s.c.) into
naive mice. A week later, similarly treated CD11bþGr1þ
cells alone were infused i.v. (Figure 3e). Melanoma in mice
co-injected with undepleted suppressor cells grew markedly
larger than cohorts infused with B16 cells alone, whereas
tumors in mice treated with DC-HIL-depleted CD11bþGr1þ
cells were similar to those given B16 alone. This outcome for
DC-HIL depletion was not observed using Rag2 KO mice
(Supplementary Figure S5 online), suggesting that T cells were
involved. Experiments using DC-HIL-deficient CD11bþGr1þ
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Figure 2. Melanoma induces DC-HIL expression by most potent CD11bþGr1þ suppressors. (a) Splenocytes from B16 melanoma-bearing or tumor-free mice
(n¼ 3) were assayed for % DC-HILþ cells in three myeloid populations. (b, c) CD11bþGr1þ (CGr1) cells isolated from mice with (b) or without (c) melanoma
were examined for the expression of Gr1 and co-inhibitory receptors (%). (d) These myeloid cells (increasing cell ratios) were cocultured with carboxyfluorescein
succinimidyl ester (CFSE)-labeled T cells activated by anti-CD3/CD28 Ab. T-cell proliferation (%) was determined by FACS (histograms). (e) Purified myeloid cells
were examined for T cell–stimulatory capacity. Different numbers of myeloid cells were pulsed with gp100 Ag and added to a culture of CD8þ pmel-1 T cells.
Culture of T cells with Ag served as control (No). T-cell proliferation was measured by 3H-thymidine (TdR) incorporation. *Po0.01.
J-S Chung et al.
DC-HIL on Myeloid Suppressor Cells
2786 Journal of Investigative Dermatology (2014), Volume 134
34
*
10
DC-HIL+
2 *
6
8
* * *
0
1 *
2
4
Spl
CGr1
++++++ + + +
+++++ + +
+ + +
No
0
–
– –
– – – –
Ab 50 25
IgG IgG αDC-HILαDC-HIL
1212 25 Cell ratio
3
PBS3
* 2
*
α
D
C-
HI
L
α
PD
-L
1
2
α
CD
80
α
CD
86
*R
at
 Ig
G
1 *
1
Spl 0
0
Day after inoculation
1
0
Spl+CGr1
Mice injected: CGr1 from:
WTKOPBS
No CGr1/CD8T
0 20 40 60 80
*
4
Gr-1
3
WT
2
0
1
0 0.12 0.25 0.5 1 0.12 0.25 0.5 1
CGr1/Spl
3
No CGr1
WT-CGr1
*
2
KO-CGr1
*
*1
Day after inoculation
0
0
KO
3 H
-T
dR
 (x
10
4  
cp
m
)
3 H
-T
dR
 (x
 10
4  
cp
m
)
3 H
 -T
dR
 (x
10
4  
cp
m
)
3 H
-T
dR
 (x
10
4  
cp
m
)
5025 5025 50
10.50.25
DC-HILnegCGr1
R
ab
 Ig
G
μg ml –150 2512
DC-HIL+CG1/CD8T
DC-HILnegCGr1/CD8T
# IFN-γ+ cells/2 x 105 LN
D
C-
HI
L
1715131197
DC-HILnegCGr1
DC-HIL+CGr1
Tu
m
or
 v
ol
 (c
m3
)
Tu
m
or
 v
ol
um
e 
(cm
3 )
CD11bneg/Spl
17151310
Figure 3. DC-HIL mediates T cell–suppressor activity of CD11bþGr1þ (CGr1) cells. (a, b) CGr1 cells from melanoma-bearing mice were cocultured with pmel-1
splenocytes (Spl), gp100 Ag, and anti-DC-HIL mAb (a), anti-co-inhibitor antibody (Ab), or control IgG (b). 3H-TdR incorporation was measured. (c) Undepleted
(DC-HILþ ) or DC-HIL-depleted (DC-HILneg) CGr1 (Supplementary method) were assayed for the suppression of pmel-1 splenocyte proliferation triggered by Ag
(increasing ratios). (d) Mice (n¼ 5) injected with pmel-1 CD8þ T cells and DC-HILþCGr1 or DC-HILnegCGr1. Ten days after giving gp100, IFN-g-producing cells
in lymph node (LN) were counted. (e) Tumor growth following co-injection of DC-HILþ or DC-HILneg CGr1 cells with B16 cells s.c. into naive mice (n¼5). Using
similar methods, DC-HIL /CGr1 cells were compared with DC-HILþ /þ counterparts for DC-HIL expression by FACS (f), T cell–suppressing ability (g), and
tumor-promoting ability (CD11bneg cells as control) (h). *Po0.01.
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cells from KO mice did not suppress T-cell activation or
promote melanoma progression (Figure 3f–h). Thus, DC-HILþ
CD11bþGr1þ cells were critical suppressors of T cells and
promoters of melanoma growth.
IFN-c and NO-mediated T cell–suppressive activity of
CD11bþGr1þ cells
We addressed the contribution of soluble factors to T-cell
suppression by adding specific inhibitors to cocultures of
pmel-1 splenocytes and CD11bþGr1þ cells. Neutralizing
Ab to TGF-b (Filipazzi et al., 2007) or IL-10 (Wang et al.,
2010) had no effect on suppressor activity, whereas anti-IFN-g
Ab blocked suppression completely (Figure 4a). Chemical
inhibitors for arginase and indoleamine restored T-cell
activation marginally, and catalase and superoxide dismutase
for neutralizing reactive oxygen species had no effect
(Figure 4b). By contrast, inhibitors of all NOS molecules or
those specific to NOS-2 blocked suppressor function substan-
tially or completely. Thus, IFN-g and NOS-2 independently
mediated suppressor activity of CD11bþGr1þ cells induced
by melanoma.
T-cell expression of SD-4 is required for CD11bþGr1þ cells’
suppressor activity
As the inhibitory function of DC-HIL on APC requires ligation
of SD-4 on T cells, a similar mechanism was likely for
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Figure 4. Cross-linked DC-HIL on CD11bþGr1þ cells induces tyrosine phosphorylation and IFN-c/iNOS expression. (a–c) CD11bþGr1þ (CGr1) cells
cocultured with pmel-1 splenocytes (1:1 ratio) with inhibitors, including (a) anti-cytokine antibody (Ab), (b) 5 mM L-NG-monomethyl-arginine citrate (NOSs),
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CD11bþGr1þ cells. DC-HIL-Fc, which interferes with
DC-HIL/SD-4 binding (Chung et al., 2007b), restored T-cell
activation dose dependently, whereas control Ig did not
(Figure 4c). For SD-4 specificity, we compared the effects of
CD11bþGr1þ cells on SD-4þ /þ versus SD-4 / pmel-1
splenocytes with gp100 Ag (Figure 4d). Without CD11bþ
Gr1þ cells, splenocytes from both mice exhibited similar
T-cell proliferation, whereas their presence inhibited SD-4þ /þ
(but not SD-4 / ) T-cell activation. Thus, melanoma-induced
CD11bþGr1þ cells inhibited T-cell activation via binding to
SD-4.
Cross-linked DC-HIL induced tyrosine phosphorylation and
expression of IFN-c and NOS-2 (iNOS) by CD11bþGr1þ cells
As DC-HIL has an intracellular ITAM (Shikano et al., 2001),
we posited that ligation of DC-HIL would activate CD11bþ
Gr1þ cells’ suppressor function via ITAM. Cross-linking
DC-HIL with specific Ab induced tyrosine phosphorylation
on the receptor (Figure 4e), as shown using transfection
experiments (Chung et al., 2009).
Does activated DC-HIL induce IFN-g and iNOS in CD11bþ
Gr1þ cells? IFN-g messenger RNA in CD11bþGr1þ cells was
markedly increased a day after DC-HIL cross-linking, followed
by a quick fall (Figure 4f). IFN-g was the predominant cytokine
secreted, followed by TNF-a, but neither IL-10 nor TGF-b
were secreted (Figure 4g). Cross-linked DC-HIL also induced
iNOS expression fourfold greater than control (Figure 4h).
Among NOS species, iNOS was most abundantly expressed,
consistent with its known selective inducibility by IFN-g
(Kamijo et al., 1994) and supported by increased NO
after DC-HIL cross-linking (Figure 4i). These outcomes were
not seen in DC-HIL /CD11bþGr1þ cells (Supplementary
Figure S6 online).
Anti-DC-HIL mAb treatment of melanoma-bearing mice
suppressed tumor growth and reduced circulating
CD11bþGr1þ cells
We next assessed the effects of the mAb on melanoma growth
and frequency of CD11bþGr1þ cells in blood. Because these
cells begin to accumulate in spleen 6 days after tumor
inoculation (when tumors reach B0.1 cm3) (Cheng et al.,
2008), we injected anti-DC-HIL mAb intraperitonealy then
and every other day, for six treatments. In mice treated with
control IgG, melanoma grew aggressively, in proportion to the
frequency of blood CD11bþGr1þ cells. The mAb markedly
suppressed subsequent melanoma growth (Figure 5a) and pre-
vented expansion of CD11bþGr1þ cells in blood (Figure 5b
and c): the latter effect was supported by the inability of KO
mice to expand CD11bþGr1þ cells (Supplementary Figure S7
online). It also significantly enhanced the IFN-g response by
T cells from mice with melanoma (Figure 5d). Blocked
expansion may be due to reduced tumor size with less
secretion of relevant soluble factors.
Inhibited CD11bþGr1þ cell function accounted for the
beneficial effects of anti-DC-HIL mAb on melanoma
Because DC-HIL is expressed by B16 cells, APC, and CD11bþ
Gr1þ cells, we compared their respective contributions via
effects of anti-DC-HIL mAb. For DC-HIL on melanoma itself,
we implanted DC-HIL-knocked-down B16 cells (KD-B16) into
WT mice, while injecting the mAb as before (Figure 5e). In this
assay, in which CD11bþGr1þ cells and APCs were both DC-
HILþ , KD-B16 tumor hardly grew in mice treated with anti-
DC-HIL mAb. Thus, DC-HIL on melanoma was not critical to
the overall effect of anti-DC-HIL mAb. When DC-HILþ DCs
were infused into DC-HIL / mice bearing DC-HILþ B16
tumor, mAb treatment had no significant effect on the APC
function (Supplementary Figure S8 online). Finally, we gave
the mAb to DC-HIL / mice inoculated with B16 cells and
CD11bþGr1þ cells (both DC-HILþ ), and it blocked tumor
promotion (Figure 5f), indicating that its beneficial effects are
due primarily to neutralizing CD11bþGr1þ cells’ function.
DC-HIL was not required for growth of EL-4 lymphoma and LL2
lung carcinoma
Does DC-HIL contribute to the growth of other malignancies?
EL-4 or LL2 cells implanted s.c. into DC-HIL / or WT mice
showed no significant difference in growth (Figures 6a,
P40.05). Neither tumor was associated with significant
DC-HIL expression on CD11bþGr1þ cells (Figure 6b). Using
the carboxyfluorescein succinimidyl ester-dilution assay
(Figure 6c), CD11bþGr1þ cells from spleen of mice with
LL2 or EL-4 tumor showed some suppressor activity that was
significantly weaker than those from melanoma. Thus, DC-HIL
did not contribute to the growth of EL-4 and LL2 malignancies.
Inducible DC-HIL expression by CD11bþGr1þ cells required
IL-1b and IFN-c
To identify inducers of DC-HIL expression on CD11bþGr1þ
cells, we examined soluble factors that are known to activate
these cells from lineage marker–negative (Linneg) BM cells
cultured in GM-CSF/IL-4 (Cheng et al., 2008). GM-CSF/IL-4
treatment alone generated 80% CD11bþGr1þ cells, without
significant DC-HIL expression. IL-1b, IFN-g, and TNF-a each
induced DC-HIL expression by 20–40% (Figure 6d). Com-
bined IL-1b and IFN-g treatment amplified DC-HIL expression
to 60%. TNF-a enhanced the effects of IL-1b and of IFN-g,
while suppressing CD11bþGr1þ cell proliferation. Thus,
IL-1b and IFN-g synergistically triggered DC-HIL expression
by CD11bþGr1þ cells.
Could differential secretion of cytokines account for the
distinctive behavior of B16 melanoma versus other tumors?
Because B16 cells in vitro did not secrete IL-1b or IFN-g
(Supplementary Figure S9 online), we assayed blood cytokines
from mice bearing B16, LL2, or EL-4 tumor (Figure 6e). Serum
IL-1b and IFN-g were elevated significantly in mice with
melanoma, but not in mice with other tumors, tumor-free
mice, or KO mice with melanoma. No other cytokines tested
were expressed preferentially by mice with melanoma,
thereby linking melanoma to IL-1b/IFN-g secretion by host
cells.
Do IL-1b and IFN-g induce CD11bþGr1þ cells to express
DC-HIL? We injected both cytokines into LL2 tumors on mice
and examined tumor-infiltrating CD11bþGr1þ cells for DC-
HIL expression (Figure 6f). Injection of either cytokine induced
marginal expression by LL2-infiltrating CD11bþGr1þ cells.
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Co-injection of both cytokines enhanced DC-HIL expression,
and repeated concurrent injections of both IL-1b and IFN-g
(but not just either cytokine or phosphate-buffered saline)
promoted LL2 tumor growth (Figure 6g). Thus, melanoma
stromal cells may secrete IL-1b and IFN-g that activate the DC-
HIL pathway.
DISCUSSION
The detrimental effect of an expanding population of
T-cell suppressors in cancer patients is well established, but
the mechanism underlying these cells’ profound immuno-
suppression remains unclear. We now show that melanoma
is associated with an autocrine loop in which the
T cell–inhibitory receptor DC-HIL induced on CD11bþGr1þ
myelomonocytic cells promotes melanoma growth. Binding of
DC-HIL on CD11bþGr1þ cells to SD-4 on effector T cells
inactivates the latter, while also transducing ITAM signals in
the former that nudge the IFN-g/iNOS axis into secreting NO.
Although this mechanism did not apply to models of lung
carcinoma and lymphoma, it is premature to consider it
distinct for melanoma, as studies involving other malignancies
are ongoing.
Researchers have used the term MDSCs for cells coexpres-
sing CD11b and Gr1 and exerting T cell–inhibitory activity.
We have avoided the MDSC label because of phenotypic and
functional heterogeneity among these cells. In fact, we sorted
melanoma-CD11bþGr1þ cells into Ly6ChighGr1low, Ly6C-
medGr1hgih, Ly6CmedGr1low, and Ly6ClowGr1low subsets, with
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Ly6ChighGr1low monocytes as highest expressors of DC-HIL
and sole suppressors of T cells (Supplementary Figure S3d and e
online).
Because CD80, CD86, and PD-L1 deliver negative signals
to T cells through corresponding receptors (Egen et al., 2002;
Keir et al., 2007), each might mediate CD11bþGr1þ cells’
effects in melanoma-bearing mice. Indeed, these cells
expressed CD80, CD86, and PD-L1 at levels similar or
greater than DC-HIL, but only DC-HIL was responsible for
suppressor activity. This distinct DC-HIL property may be due
its transduction of bidirectional signals: binding to SD-4
activates a protein tyrosine phosphatase CD148 in T cells
(Chung et al., 2011), whereas tyrosine phosphorylation of its
ITAM motif in CD11bþGr1þ cells leads to IFN-g and iNOS
expression. Our preliminary results suggest that ligated DC-
HIL on CD11bþGr1þ cells activates Syk kinase, a major
signal mediator for ITAM (Lowell, 2011). Unlike DC-HIL,
CD80/CD86 and PD-L1 lack tyrosine-based signal motifs,
restricting them to unidirectional signaling via respective
TCRs (Carreno and Collins, 2002; Sharpe et al., 2007).
CD11bþGr1þ cells differ from APCs in the mechanism(s)
for suppressing T-cell function. The latter appears to be
focused on the downregulation of TCR signals, whereas the
former may use the same pathway plus other avenues. Thus,
classic co-inhibitors may not be as critical for CD11bþGr1þ
cells’ suppressor activity.
IFN-g might have simultaneously opposing effects on
cancers. Its well-known antitumor benefits (Kerkar et al.,
2011; Takeda et al., 2011) are mediated via activation and
proliferation of T cells and natural killer cells, whereas its
protumor effects are transmitted via MDSCs. We showed that
IFN-g’s deleterious protumor effects arise not only by inducing
DC-HIL expression on MDSCs but also by MDSCs expressing
the cytokine to mediate MDSCs’ T-cell–suppressor function.
These data are consistent with MDSCs from IFN-g / mice
with colon carcinoma that lost their suppressor activity (Gallina
et al., 2006). Indeed, we showed IFN-g / CD11bþGr1þ
cells to be poor tumor promoters, similar to DC-HIL /
CD11bþGr1þ cells (Supplementary Figure S10 online).
MDSC’s phenotypic and functional plasticity to microenvir-
onmental conditions may apply to different cancers in which
divergent soluble factors produced by the tumors or their
stromal cells drive MDSC differentiation toward particular
subsets (Condamine and Gabrilovich, 2011). IL-1b-over-
expressing breast cancer honed MDSC differentiation toward
the Gr1highLy6Cneg phenotype with highest ability to suppress
natural killer cell activity (Elkabets et al., 2010), consistent
with our DC-HIL-expressing fraction among CD11bþGr1þ
cells responsible for melanoma-induced immunosuppression.
The DC-HIL phenotype may be nurtured by IL-1b and IFN-g
secreted by melanoma stromal cells, as elicited by our
experimental administration of both cytokines into a non-
melanoma LL2 carcinoma. Highly elevated IL-1b and IFN-g
expression was reported in skin and lymph node bearing
spontaneous melanoma in a transgenic mouse model (Meyer
et al., 2011).
High DC-HIL expression on blood CD14þHLA-DRno/low
cells (the equivalent of mouse CD11bþGr1þ cells) in
melanoma patients and the restoration of suppressed T-cell
function in those patients using anti-DC-HIL mAb (see
accompanying submitted manuscript) provide further rationale
for exploring DC-HIL-expressing myelomonocytic suppressor
cells as a target for improving melanoma immunotherapy.
MATERIALS AND METHODS
Reagents, animal, cell culture, and leukocyte preparations
Antibodies were purchased from eBioscience (San Diego, CA) and
Upstate Biotechnology (Lake Placid, NY); recombinant cytokines
were purchased from Pepro Tech (Rocky Hill, NJ); and chemical
inhibitors were purchased from Sigma-Aldrich (St Louis, MO). We
generated 1E4 rat anti-mouse DC-HIL (for immunoblotting) and
UTX103 rabbit anti-mouse DC-HIL (for flow cytometric analysis
and functional blocking) (Chung et al., 2009). DC-HIL-Fc fusion
protein was produced (Chung et al., 2007b). C57BL/6 mice and pmel-
1 TCR transgenic mice were purchased from Harlan (Indianapolis, IN)
and Jackson Laboratory (West Grove, PA), respectively. The DC-
HIL / mice were generated by the deletion of exons 2 and 3
of the gene, resulting in depletion specifically of the DC-HIL protein
(Supplementary Figure S1 online). SD-4 / mice were obtained
from Dr Kojima (Nagoya University) (Ishiguro et al., 2000), and
SD-4 / pmel-1 mice were produced by breeding between these
strains.
All tumor cell lines were purchased from the American Type
Culture Collection (Manassas, VA). CGr1 and/or CD11bneg cells
were isolated from spleen, blood, or tumor-infiltrating cells of
mice (2–3 weeks after implanting with tumor cells) (Chung et al.,
2014). Depletion of DC-HILþ cells from the CGr1 preparation
was performed using UTX103 mAb-coated magnetic beads, and
BM-DC, splenic CD11cþ , or F4/80þ cells were prepared (Chung
et al., 2014).
Tumor growth assays
Tumor cells (5 105) were injected s.c. into the right shaved flank of
mice. Tumor volume was measured (Tomihari et al., 2010). Eight
days after implanting LL2 cells, phosphate-buffered saline or IL-1b
and/or IFN-g (50 ng per tumor) was injected into the tumor four times
every 2 days. CD11bþGr1þ (CGr1) cells were purified from the
tumor the day after the second injection. For lung metastasis, B16
cells (1 106) were injected into mice via the lateral tail veil. Lungs
were harvested 18 or 19 days post injection, and their weight,
metastatic foci, and melanin content were determined (Tomihari
et al., 2010).
T-cell assays
Myeloid cells purified from splenocytes of tumor-bearing mice
(2–3 weeks after implanting s.c.) were cocultured with WT-T cells
or pmel-1 splenocytes (1 105 cells per well) at varying cell ratios
with anti-CD3/CD28 Ab or gp100 peptide (each 1mg ml 1), respec-
tively, for 3 days. Inhibitors were added to splenocytes/CGr1 cells
(1:1 ratio). CGr1 cells were also cocultured with SD-4þ /þ or
SD-4 / pmel-1 splenocytes. For T cell–stimulatory assays, myeloid
cells were pulsed with 1mg ml 1 hgp100 peptide and cocultured
with pmel-1 CD8þ T cells at increasing cell ratios. After 2 days of
culture, T-cell activation was measured by carboxyfluorescein succi-
nimidyl ester-dilution assay or 3H-thymidine uptake (Chung et al.,
2007b).
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Cross-linking and soluble factor assays
CGr1 cells (5 106) were cross-linked with anti-DC-HIL mAb and
assayed for tyrosine phosphorylation (Chung et al., 2009). CGr1
cells were also cultured in 96-well plates (2 105 cells per well)
precoated with anti-DC-HIL mAb or control IgG (10mg ml 1).
After 1 or 2 days of culture, the culture supernatant and cell pellets
were collected, respectively, for cytokine secretion using ELISA and
whole-cell extracts for measuring NO2 production using Griess
method (De Santo et al., 2005) or total RNA for measuring IFN-g
and NOS messenger RNA using quantitative reverse-transcriptase–
PCR.
Antibody treatment
On day 6 or 11 after inoculating 5 105 B16 or KD-B16 cells s.c.,
mice were sorted to two groups with similar tumor volume
(B0.1 cm3) and injected intraperitonealy with Ab (200mg per mouse)
every other day for —five to six injections. At varying times, blood
was taken from tails of five representative mice per group, depleted of
red blood cells, pulsed with OVA257–264 peptide (1mg ml
 1), and
examined by FACS for % CGr1 in total H-2Kbþ cells.
Generation of CGr1 cells
Linneg BM cells isolated using the Lineage cell depletion kit (Miltenyi,
Auburn, CA) were cultured (5 105 cells per well) for 5 days with
GM-CSF/IL-4 (each 10 ng ml 1) plus cytokines (10–20mng ml 1).
Cultured cells were depleted of CD11cþ /CD19þ cells (10–15% in
total cells) and examined for % CGr1 cells and DC-HIL expression.
Adoptive transfer
For T-cell suppression, mice were injected i.v. with pmel-1 CD8þ
T cells (1 106 cells per mouse); 3 days later, they were injected i.v.
with undepleted or DC-HIL-depleted CGr1 (1 106 cells per mouse)
and vaccinated with Freund’s adjuvant/gp100 peptide (1 mg ml 1);
and 10 days later lymph node cells were restimulated by culturing for
2 days with gp100 peptide in enzyme-linked immunospot wells, and
IFN-g-secreting cells were counted. For melanoma promotion,
2 106 CGr1 and 2 105 B16 cells were co-injected s.c. into mice.
A week later, mice were injected again with CGr1 cells. Some mice
were injected intraperitonealy with Ab (200mg per mouse) starting on
day 7, every other day, for five injections.
Serum cytokines
Two weeks post implantation of tumor cells (5 105 cells per mouse),
sera were taken and albumin was removed by passing through the
Swell Blue albumin removal spin column (Pierce, Rockford, IL) before
ELISA assays for cytokines.
Statistical analysis
Statistical analyses were performed using two-sided Student’s t-test,
with P (o0.01) considered significant. All data shown are represen-
tative of at least two independent experiments.
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